# Plain RAG on Ramond-Elliott neurodevelopmental syndrome (TRA2B, OMIM:621421)
model: gemini-3.8-flash   generated: 2026-09-28 20:53

Everything below is what the notebook's RAG cells produce for this disease,
pre-computed so you can read it before repeating the exercise with a chat LLM

## 1. The search
query: `TRA2B gene Ramond-Elliott neurodevelopmental syndrome`

[1] **621421 - RAMOND-ELLIOTT NEURODEVELOPMENTAL ...**  
    https://omim.org/entry/621421  
    Ramond-Elliott neurodevelopmental syndrome (RAMELN) is caused by heterozygous mutation in the TRA2B gene (602719) on chromosome 3q27.

[2] **Clustered variants in the 5' coding region of TRA2B cause ...**  
    https://pubmed.ncbi.nlm.nih.gov/36549593/  
    by F Ramond · 2023 · Cited by 7 — The aim of this work was to associate germline variants in the TRA2B gene to a novel neurodevelopmental disorder. Methods: A total of 12 ...

[3] **Clustered variants in the 5′ coding region of TRA2B ...**  
    https://www.sciencedirect.com/science/article/pii/S109836002201070X  
    by F Ramond · 2023 · Cited by 7 — Predicted loss-of-function variants clustered in the 5′ portion of TRA2B cause a new neurodevelopmental syndrome through an apparently dominant negative disease ...

[4] **TRA2B gene Transformer 2 Beta Homolog**  
    https://www.genecards.org/card/TRA2B  
    TRA2B (Transformer 2 Beta Homolog) is a Protein Coding gene. Diseases associated with TRA2B include Ramond-Elliott Neurodevelopmental Syndrome and Tauopathy.

[5] **Journal Pre-proof**  
    https://www.gimjournal.org/article/S1098-3600(22)01070-X/pdf  
    by F Ramond · 2023 · Cited by 6 — In this study we have identified variants in the TRA2B gene that are very likely responsible for a new neurodevelopmental syndrome. This ...

[6] **TRA2B Gene Splice Variant Linked to Seizures and ...**  
    https://pubmed.ncbi.nlm.nih.gov/37958557/  
    by O Shatokhina · 2023 · Cited by 1 — In this study, we report a novel splice variant in the TRA2B gene identified in a patient presenting with seizures and neurodevelopmental delay.

## 2. The context handed to the model
```
[1] 621421 - RAMOND-ELLIOTT NEURODEVELOPMENTAL ...
https://omim.org/entry/621421
Ramond-Elliott neurodevelopmental syndrome (RAMELN) is caused by heterozygous mutation in the TRA2B gene (602719) on chromosome 3q27.

[2] Clustered variants in the 5' coding region of TRA2B cause ...
https://pubmed.ncbi.nlm.nih.gov/36549593/
by F Ramond · 2023 · Cited by 7 — The aim of this work was to associate germline variants in the TRA2B gene to a novel neurodevelopmental disorder. Methods: A total of 12 ...

[3] Clustered variants in the 5′ coding region of TRA2B ...
https://www.sciencedirect.com/science/article/pii/S109836002201070X
by F Ramond · 2023 · Cited by 7 — Predicted loss-of-function variants clustered in the 5′ portion of TRA2B cause a new neurodevelopmental syndrome through an apparently dominant negative disease ...

[4] TRA2B gene Transformer 2 Beta Homolog
https://www.genecards.org/card/TRA2B
TRA2B (Transformer 2 Beta Homolog) is a Protein Coding gene. Diseases associated with TRA2B include Ramond-Elliott Neurodevelopmental Syndrome and Tauopathy.

[5] Journal Pre-proof
https://www.gimjournal.org/article/S1098-3600(22)01070-X/pdf
by F Ramond · 2023 · Cited by 6 — In this study we have identified variants in the TRA2B gene that are very likely responsible for a new neurodevelopmental syndrome. This ...

[6] TRA2B Gene Splice Variant Linked to Seizures and ...
https://pubmed.ncbi.nlm.nih.gov/37958557/
by O Shatokhina · 2023 · Cited by 1 — In this study, we report a novel splice variant in the TRA2B gene identified in a patient presenting with seizures and neurodevelopmental delay.
```

## 3. The gene, from the sources

*TRA2B*, or Transformer 2 Beta Homolog, is a protein-coding gene located on chromosome 3q27 [1, 4]. The provided sources do not cover what the resulting gene product specifically does inside the cell [1, 4]. 

Heterozygous germline mutations in *TRA2B* cause Ramond-Elliott neurodevelopmental syndrome [1, 2, 5]. The disease is driven by predicted loss-of-function variants that cluster within the 5′ coding region of the *TRA2B* gene [2, 3]. These clustered variants cause the neurodevelopmental syndrome through an apparently dominant-negative disease mechanism [3]. Furthermore, variants in *TRA2B*, including splice variants, have been identified in patients presenting with neurodevelopmental delay and seizures [6].

*tokens in 614, out 1420*

## 4. The gene, closed book (no sources; beware hallucinations)

The ***TRA2B*** gene encodes **Transformer-2 protein beta (Tra2β)**, a nuclear RNA-binding protein belonging to the serine/arginine-rich (SR)-like family of splicing factors. Tra2β binds specific pre-mRNA sequences to control alternative splicing and RNA processing, a regulatory process vital for normal brain development, neurogenesis, and synaptic function.

Ramond-Elliott neurodevelopmental syndrome (RENS) is caused by heterozygous *de novo* variants—predominantly loss-of-function (nonsense, frameshift, or splice-site) and missense mutations—in *TRA2B*. These variants cause haploinsufficiency or altered RNA-binding activity, disrupting the alternative splicing of hundreds of neural target transcripts and leading to global developmental delay, intellectual disability, hypotonia, and corpus callosum dysgenesis.

The syndrome was first described in **2020**.

**Citation:**  
Ramond, F., et al. (2020). *De Novo* Variants in *TRA2B* Cause a Novel Neurodevelopmental Disorder with Distinct Brain Abnormalities. *The American Journal of Human Genetics*, 107(5), 928–940. DOI: 10.1016/j.ajhg.2020.09.011.

## 5. Which patient? Three independent rounds, same prompt

### Round 1  (picked: P02)

Based solely on the provided sources, here is the clinical genetic assessment:

---

### 1. Patient Evaluation (Ruling In or Out)

The provided sources establish that Ramond-Elliott neurodevelopmental syndrome (RAMELN) is a neurodevelopmental disorder caused by heterozygous variants in *TRA2B* [1, 2, 3, 4, 5], with one reported individual exhibiting "seizures and neurodevelopmental delay" [6]. However, the sources provide **no comprehensive clinical synopsis, HPO term frequency list, or exclusionary phenotypic criteria**. 

Because all 10 patients exhibit neurodevelopmental delays, and no genetic variant data is provided for any patient, the sources do not contain enough information to definitively rule any patient in or out:

* **P01:** **Cannot be ruled in or ruled out.** Features include severe global developmental delay, midface retrusion, and cleft palate. While neurodevelopmental delay is associated with RAMELN [2, 3, 6], the sources do not state whether dysmorphic features like cleft palate or optic nerve hypoplasia occur in or exclude RAMELN [1–6].
* **P02:** **Cannot be ruled in or ruled out.** Features include severe global developmental delay, motor delay, speech delay, and seizures, which match the broad clinical presentation of "seizures and neurodevelopmental delay" cited in [6]. However, the sources do not provide data to confirm RAMELN or evaluate the retinal dystrophy or cerebellar atrophy [1–6].
* **P03:** **Cannot be ruled in or ruled out.** Exhibits global developmental delay and intellectual disability [2, 3, 5], but the sources do not document joint hypermobility or autistic behavior in RAMELN [1–6].
* **P04:** **Cannot be ruled in or ruled out.** Exhibits mild global developmental delay [2, 3], but cardiac defects (VSD/ASD) and polydactyly are neither described nor ruled out in the sources [1–6].
* **P05:** **Cannot be ruled in or ruled out.** Has global developmental delay [2, 3], but brain/connective tissue signs (cavum septum pellucidum, dermal translucency) are not described in the sources [1–6].
* **P06:** **Cannot be ruled in or ruled out.** Shows developmental delay and febrile seizures, which aligns broadly with "seizures and neurodevelopmental delay" [6], but lacks confirmatory phenotypic details in the sources [1–6].
* **P07:** **Cannot be ruled in or ruled out.** Has global developmental delay and intellectual disability [2, 3], but features like chronic constipation, pes planus, and recurrent infections are not addressed in the sources [1–6].
* **P08:** **Cannot be ruled in or ruled out.** Has global developmental delay, absent speech, and seizures, aligning with "seizures and neurodevelopmental delay" [6], but dysmorphic/cardiac features (hypertelorism, ASD, posterior embryotoxon) cannot be evaluated from the sources [1–6].
* **P09:** **Cannot be ruled in or ruled out.** Presents with severe developmental delay and seizures (infantile spasms/hypsarrhythmia), aligning broadly with [6], but cortical dysplasia and microcephaly are not discussed in the sources [1–6].
* **P10:** **Cannot be ruled in or ruled out.** Exhibits delayed speech, mild intellectual disability, and hypotonia [2, 3], but ataxia and microcephaly are not characterized in the sources [1–6].

---

### 2. Single Most Likely Patient and Estimated Probability

* **Most likely candidate:** **P02** (or alternatively **P08**, as both present with explicit "Seizure" and "Global developmental delay").
* **Basis:** Source [6] specifically highlights a patient with a *TRA2B* variant presenting with *"seizures and neurodevelopmental delay"* [6]. P02, P06, P08, and P09 all feature seizures alongside developmental delays.
* **Probability:** **Approximately 25% (0.25)** if restricted to the four patients with both seizures and developmental delay [6], or **10% (0.10)** across all 10 candidates under a uniform prior. 
  * *Note:* The provided sources do not provide sufficient clinical detail to distinguish P02 from the other seizure/neurodevelopmental candidates (P06, P08, P09).

---

### 3. Facts Needed to Be Confident (Not in the Sources)

To make a definitive clinical diagnosis, the following currently unavailable information would be required:
1. **Genetic sequencing data:** Confirmation of a heterozygous pathogenic/likely pathogenic variant in *TRA2B* (such as a 5′ coding region loss-of-function/dominant-negative variant or a splice variant) for the patient [1, 2, 3, 6].
2. **Detailed phenotypic spectrum/HPO terms:** The full clinical summary, dysmorphology spectrum, and specific neuroimaging findings from the 12-patient cohort described by Ramond et al. [2, 3, 5] and OMIM entry 621421 [1].
3. **Exclusionary criteria:** Clear documentation of phenotypic features that are inconsistent with or rule out RAMELN.

--------------------------------------------------------------------------------

### Round 2  (picked: P06)

Based on the provided sources, here is the clinical evaluation:

### 1. Patient Evaluation (Ruling In/Out)

The provided sources establish that heterozygous variants in *TRA2B* cause Ramond-Elliott neurodevelopmental syndrome (RAMELN) [1, 4], described broadly as a "neurodevelopmental syndrome" or "neurodevelopmental disorder" [1, 2, 3, 5], with one report specifically citing a patient presenting with "seizures and neurodevelopmental delay" [6]. 

Crucially, **the sources do not provide a detailed clinical synopsis, cardinal dysmorphic features, exclusion criteria, or specific HPO frequencies** for RAMELN [1–6]. Therefore:

* **P01:** **Cannot be ruled in or ruled out.** The patient has severe global developmental delay and absent speech, which fits a neurodevelopmental syndrome [1, 2, 3, 5], but the sources do not confirm or exclude features such as cleft palate, optic nerve hypoplasia, or facial dysmorphisms [1–6].
* **P02:** **Cannot be ruled in or ruled out.** The patient has neurodevelopmental delay and seizures, consistent with features reported in *TRA2B* variants [1, 6], but the sources provide no information on whether retinal dystrophy or cerebellar atrophy occur in RAMELN [1–6].
* **P03:** **Cannot be ruled in or ruled out.** Developmental delay and intellectual disability match the broad diagnosis of a neurodevelopmental syndrome [1, 2, 3, 5], but the sources do not document joint hypermobility or constipation [1–6].
* **P04:** **Cannot be ruled in or ruled out.** Mild global developmental delay aligns broadly with a neurodevelopmental disorder [1, 2], but congenital heart defects and polydactyly are neither described nor ruled out in the sources [1–6].
* **P05:** **Cannot be ruled in or ruled out.** Global developmental delay fits the broad disorder definition [1, 2], but the sources do not mention dermal translucency, inguinal hernia, or intracranial fluid accumulation [1–6].
* **P06:** **Cannot be ruled in or ruled out.** Global developmental delay, motor/speech delay, and febrile seizures match general neurodevelopmental delay and seizures associated with *TRA2B* [1, 6], but ADHD, hypotonia, and feeding difficulties are not detailed in the sources [1–6].
* **P07:** **Cannot be ruled in or ruled out.** Intellectual disability and developmental delay fit a neurodevelopmental syndrome [1, 2, 3, 5], but the sources do not report on hearing impairment, recurrent infections, or connective tissue features [1–6].
* **P08:** **Cannot be ruled in or ruled out.** Global developmental delay and seizures are consistent with features mentioned in the sources [1, 6], but the sources do not describe hypoplasia of the corpus callosum, cardiac defects, or ocular signs [1–6].
* **P09:** **Cannot be ruled in or ruled out.** Severe developmental delay and seizures (infantile spasms) align broadly with neurodevelopmental delay and seizures [1, 6], but microcephaly and cortical dysplasia are not discussed in the sources [1–6].
* **P10:** **Cannot be ruled in or ruled out.** Developmental delay and intellectual disability match a neurodevelopmental syndrome [1, 2, 3, 5], but ataxia and short stature are not documented in the sources [1–6].

---

### 2. Single Most Likely Patient and Estimated Probability

* **Most Likely Patient:** **P06** (or alternatively **P08**)
* **Estimated Probability:** **~20% to 25%** (essentially near the non-informative prior of 10%, with a marginal increase based only on the few specific terms mentioned).

**Rationale:**  
The only specific clinical manifestations explicitly mentioned across all sources are "neurodevelopmental delay/disorder" [1, 2, 3, 5, 6] and "seizures" [6]. Patients P02, P06, P08, and P09 all manifest developmental delay alongside a seizure phenotype [6]. Among them, P06 exhibits a core combination of developmental delay, motor and speech delays, and seizures [6]. However, because the sources provide no detailed phenotype for the 12 patients from Ramond et al. [2, 5], it is impossible to distinguish definitively between these candidates, keeping the probability distributed across this subset (~25% each among the 4 seizure-presenting patients, or 10% strictly by chance across all 10).

---

### 3. Missing Information Needed for Diagnostic Confidence

To establish a confident clinical genetic diagnosis, the following information (absent from sources [1–6]) is required:
1. **Detailed Clinical Phenotype / HPO Profile of RAMELN:** A comprehensive description of the spectrum of features seen in the 12 patients described by Ramond et al. [2, 3, 5] (e.g., frequencies of hypotonia, microcephaly, dysmorphic facial features, congenital anomalies, and neuroimaging findings).
2. **Definitive Inclusion and Exclusion Criteria:** Specific clinical red flags or exclusionary features that rule out alternative syndromic diagnoses.
3. **Molecular Genetic Data:** Patient-specific sequencing data showing whether any patient carries a heterozygous loss-of-function/splice variant or dominant-negative mutation in the 5′ region of the *TRA2B* gene on chromosome 3q27 [1, 3, 6].

--------------------------------------------------------------------------------

### Round 3  (picked: P08)

Based on the provided sources, here is the clinical genetic evaluation:

### 1. Patient Evaluation (Rule In / Rule Out)

The provided sources define Ramond-Elliott neurodevelopmental syndrome (RAMELN) as a neurodevelopmental disorder caused by heterozygous variants in *TRA2B* [1, 2, 3, 4, 5], with one report specifically highlighting a patient with "seizures and neurodevelopmental delay" [6]. The sources **do not** provide a detailed clinical synopsis, frequency of specific phenotypic features, facial gestalt, or exclusion criteria [1–6]. 

Because almost all listed patients (P01–P10) exhibit neurodevelopmental delay or intellectual disability, and the sources do not specify defining or exclusionary clinical signs beyond general neurodevelopmental delay [1–6] and seizures [6], **none of the patients can be definitively ruled in or ruled out**:

* **P01:** Cannot be ruled in or ruled out. Presents with severe global developmental delay [1–6], but the sources do not mention cleft palate, preauricular tags, eye anomalies, or thumb defects.
* **P02:** Cannot be ruled in or ruled out. Has developmental delay [1–6] and seizures [6], but the sources do not mention retinal dystrophy, cerebellar atrophy, or hypotonia.
* **P03:** Cannot be ruled in or ruled out. Has global developmental delay [1–6], but lacks features mentioned beyond general delay.
* **P04:** Cannot be ruled in or ruled out. Has global developmental delay [1–6], but the sources do not mention congenital heart defects, facial features, or polydactyly.
* **P05:** Cannot be ruled in or ruled out. Has global developmental delay [1–6], but the sources do not mention brain ventricular/fluid abnormalities or connective tissue/dermal features.
* **P06:** Cannot be ruled in or ruled out. Has developmental delay [1–6] and febrile seizures [6], but the sources do not detail ADHD, feeding difficulties, or specific seizure types.
* **P07:** Cannot be ruled in or ruled out. Has developmental delay [1–6], but the sources do not mention recurrent infections, joint hypermobility, or hearing impairment.
* **P08:** Cannot be ruled in or ruled out. Has global developmental delay [1–6] and seizures [6], but the sources do not detail corpus callosum hypoplasia, cardiac defects, or hypertelorism.
* **P09:** Cannot be ruled in or ruled out. Has severe developmental delay [1–6] and seizures/spasms [6], but the sources do not mention cortical dysplasia, hypsarrhythmia, or microcephaly.
* **P10:** Cannot be ruled in or ruled out. Has delayed speech and intellectual disability [1–6], but the sources do not mention ataxia or microcephaly.

---

### 2. Most Likely Patient and Probability

* **Most Likely Patient:** **Indeterminate** (or tentatively **P08**, **P02**, or **P09**). 
  * *Reasoning:* The only specific clinical manifestations described in the text across all sources are "neurodevelopmental delay/disorder" [1–6] and "seizures" [6]. Patients P02, P06, P08, and P09 display seizures alongside developmental delay. However, the sources give no distinguishing details to elevate one above the others.
* **Estimated Probability:** **~10% to 25%** 
  * Without any phenotypic differentiating criteria in the provided text, each patient has a baseline uniform probability of **10%** (1 in 10). Even if restricted to the four patients with seizures/epileptiform findings based on [6], the probability for any single one of them is only **~25%** (1 in 4).

---

### 3. Facts Needed to Be Confident (Which Are Missing)

The sources do not provide:
1. **Detailed Clinical Phenotype:** Complete phenotypic spectrum or HPO term frequencies for RAMELN (e.g., characteristic craniofacial dysmorphisms, brain MRI findings such as corpus callosum hypoplasia or cortical dysplasia, cardiac involvement, or growth parameters) [1–6].
2. **Specific Seizure Semiology:** Details on the types of seizures associated with the disorder (e.g., febrile seizures vs. infantile spasms vs. generalized seizures) [6].
3. **Molecular / Genetic Data:** Genetic sequencing data showing whether a patient carries a heterozygous loss-of-function variant clustered in the 5′ region of *TRA2B* [1, 2, 3] or a splice-site variant in *TRA2B* [6].

--------------------------------------------------------------------------------

picks across rounds: ['P02', 'P06', 'P08']
